Assessing the effects of transforming growth factor-beta1 on bladder smooth muscle cell phenotype. I. Modulation of in vitro contractility. Parekh A, Long RA, Iannone EC, Chancellor MB, Sacks MS (2009) J Urol 182: 1210-5 Outcomes of incontinent ileovesicostomy in the pediatric patient. Ching CB, Stephany HA, Juliano TM, Clayton DB, Tanaka ST, Thomas JC, Adams MC, Brock JW, Pope JC (2014) J Urol 191: 445-50 Re: Treatment Outcomes and Resource Use of Patients With Neurogenic Detrusor Overactivity Receiving Botulinum Toxin A (BOTOX) Therapy in Germany. Penson DF (2011) J Urol 185: 1383-4 Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. Padmanabhan P, Scarpero HM, Milam DF, Dmochowski RR, Penson DF (2011) World J Urol 29: 51-7 Nonclinical Barriers to Care for Neurogenic Patients Undergoing Complex Urologic Reconstruction. Sosland R, Kowalik CA, Cohn JA, Milam DF, Kaufman MR, Dmochowski RR, Reynolds WS (2019) Urology 124: 271-275 Development of upper tract stones in patients with congenital neurogenic bladder. Stephany HA, Clayton DB, Tanaka ST, Thomas JC, Pope JC, Brock JW, Adams MC (2014) J Pediatr Urol 10: 112-7
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.